In January 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval for the antibody treatment Lecanemab for Alzheimer’s disease. This treatment aims to clear pathological amyloid deposits in the brain, similar to Aducanumab, which was approved for the same indication. Finally, on July 2, 2024, the FDA also approved the antibody Donanemab for the treatment of mild cognitive impairment or early-stage dementia in Alzheimer’s disease.